Could neoadjuvant chemotherapy increase postoperative complication risk of laparoscopic total gastrectomy? A mono-institutional propensity score-matched study in China

Table 4 Clinical characteristics and surgical indicators in pTNM 0-II patients between laparoscopic total gastrectomy after neoadjuvant chemotherapy and laparoscopic total gastrectomy group

Variable	NC-LTG group (n = 39)	LTG group (n = 40)	P value
Sex			0.560
Male	28	31
Female	11	9
Age (yr, mean ± SD)	59.56 ± 10.67	58.73 ± 12.08	0.745
BMI (kg/m2, mean ± SD)	23.08 ± 2.71	22.20 ± 4.25	0.275
ASA grade			0.508
I	3	1
II	31	38
III	5	1
Surgical time, min (mean ± SD)	249.38 ± 48.62	223.85 ± 50.13	0.024
Blood loss, mL (median, IQR)	100 (100-200)	100 (100-150)	0.067
Retrieved lymph nodes, n (mean ± SD)	30.67 ± 11.53	32.73 ± 13.07	0.461
Fist flatus day, d [(median, IQR)]	4.0 (3.0-5.0)	4.5 (3.0-5.0)	0.741
R0 resection rate, n (%)	2 (5.1)	0 (0)	0.241
Postoperative day, d [(median, IQR)]	9.0 (7.0-10.0)	9.0 (7.0-11.0)	0.724
Total complication rate, n (%)	9 (23.1)	4 (10.0)	0.117
Severe complication rate, n (%)	2 (5.1)	1 (2.5)	0.982

NC-LTG: Laparoscopic total gastrectomy after neoadjuvant chemotherapy; LTG: Laparoscopic total gastrectomy; BMI: Body mass index; ASA: American Society of Anesthesiologists; IQR: Interquartile range.